Suppliers / Valdepharm

Valdepharm

France Updated 9 July 2026

Valdepharm is an API manufacturer based in France. It holds 6 active US drug master files across a filed portfolio of 10 molecules. Its GMP standing is certified by ANSM (FR), EMA and MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 21 January 2022 as VAI.

6
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 21 January 2022 VAI US FDA
  • 10 July 2014 NAI US FDA
  • 25 May 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Cedex, United Arab Emirates Not on file
VAL DE REUIL, France Not on file
VAL-DE-REUIL, France Not on file
Val De Reuil Cedex, France Not on file
France, France 3000538143

What they file, and where

Molecule Regulators Docs
Estradiol SFDA (Saudi Arabia), US FDA 3
Norethisterone US FDA 2
Estradiol Valerate US FDA 1
Relebactam SFDA (Saudi Arabia) 1
Trazodone US FDA 1
エストラジオール吉草酸エステル PMDA (Japan) 1
エストラジオール水和物 PMDA (Japan) 1
トラゾドン塩酸塩 PMDA (Japan) 1
無菌アリピプラゾール水和物 PMDA (Japan) 1
酢酸ノルエチンドロン PMDA (Japan) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EDE (AE) 1 None
ANSM (FR) None 48
EMA None 2
MFDS (Korea) None 2

Scale

Year Revenue Exports Destinations
2024 $115.8M Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Valdepharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 January 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported